© 2026 Stocks Telegraph All rights reserved.
Most stock quote data provided by Financial Modeling Prep
DexCom, Inc. (DXCM) stock surged +1.99%, trading at $84.68 on NASDAQ, up from the previous close of $83.03. The stock opened at $83.92, fluctuating between $83.76 and $84.98 in the recent session.
| Filing Date | Accepted Date | |
|---|---|---|
| Filing Date | Accepted Date | |
|---|---|---|
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 14, 2026 | 83.92 | 84.98 | 83.76 | 84.68 | 2.46M |
| Sep 11, 2026 | 84.65 | 85.82 | 82.83 | 83.03 | 2.44M |
| Sep 10, 2026 | 83.27 | 84.82 | 82.29 | 84.51 | 3.49M |
| Sep 09, 2026 | 83.93 | 85.16 | 82.80 | 83.88 | 3.95M |
| Sep 08, 2026 | 86.59 | 86.75 | 84.24 | 84.53 | 8.08M |
| Sep 04, 2026 | 88.78 | 89.00 | 87.65 | 87.90 | 2.27M |
| Sep 03, 2026 | 89.73 | 91.00 | 89.05 | 89.71 | 1.56M |
| Sep 02, 2026 | 90.03 | 91.90 | 89.54 | 89.69 | 1.82M |
| Sep 01, 2026 | 90.83 | 92.34 | 89.91 | 90.14 | 2.12M |
| Aug 31, 2026 | 90.00 | 91.18 | 89.09 | 91.06 | 2.99M |
| Aug 28, 2026 | 89.81 | 90.84 | 88.83 | 90.82 | 2.54M |
| Aug 27, 2026 | 88.37 | 90.43 | 87.60 | 89.29 | 3.01M |
| Aug 26, 2026 | 88.17 | 89.76 | 87.51 | 88.96 | 3.82M |
| Aug 25, 2026 | 90.73 | 91.14 | 88.78 | 89.16 | 4.11M |
| Aug 24, 2026 | 92.30 | 92.59 | 91.03 | 91.06 | 4.4M |
| Aug 21, 2026 | 89.61 | 92.56 | 89.20 | 92.34 | 3.48M |
| Aug 20, 2026 | 89.42 | 91.39 | 89.28 | 90.22 | 5.09M |
| Aug 19, 2026 | 90.30 | 91.92 | 89.24 | 89.88 | 8.63M |
| Aug 18, 2026 | 89.49 | 91.50 | 88.98 | 89.60 | 3.35M |
| Aug 17, 2026 | 89.34 | 89.90 | 88.15 | 88.76 | 3.57M |
DexCom, Inc. is a medical technology company primarily focused on innovating, developing, and marketing continuous glucose monitoring (CGM) systems. Operating across the United States and internationally, the firm provides its solutions for individuals managing diabetes as well as for healthcare practitioners. Its product portfolio features the DexCom G6, a comprehensive CGM system for diabetes management; the Dexcom Real-Time API, enabling authorized third-party developers to integrate live CGM data into their digital health applications; the Dexcom ONE, which aims to supersede traditional finger-prick blood glucose testing for treatment decisions; and Dexcom Share, a remote monitoring platform. The company is also developing the Dexcom G7, its next-generation CGM system. Furthermore, DexCom, Inc. has a licensing and collaboration agreement with Verily Life Sciences LLC and Verily Ireland Limited to advance blood-based or interstitial glucose monitoring products. The company directly sells its offerings to specialists such as endocrinologists, physicians, and diabetes educators. DexCom, Inc. was founded in 1999 and maintains its headquarters in San Diego, California.
| Employees | 11050 |
| Beta | 1.42 |
| Sales or Revenue | $3.62B |
| 5Y Sales Change% | 2.209% |
| Fiscal Year Ends | December |
| Sector | Healthcare |
| Industry | Medical - Devices |